Market Overview

UPDATE: Morgan Stanley Raises PT to $83 on Celgene on Abraxane-Driven Growth Outlook

Share:
Related CELG
Pipeline Bomb: Analysts Review Celgene's Crohn's Diseases Failure
32 Stocks Moving In Friday's Mid-Day Session
Celgene Abandons Crohn's Drug; Could Others Take Its Spot? (Investor's Business Daily)

Morgan Stanley reiterated its Overweight rating on Celgene (NASDAQ: CELG) and raised its price target from $81 to $83.

Morgan Stanley commented, "Details are scant prior to an ASCO GI data presentation (1/24-26) but we are optimistic about a clinically relevant ~1.5-2 month or better median OS benefit. For the stock, this outcome is important as Abraxane with pomalidomide and apremilast can provide much needed growth diversification away from Revlimid. … Incorporating Abraxane in pancreatic cancer into our model with ~$700MM in 2020 revenue pending the detailed Phase III data and our price target rises to $83 from $81. We assume modest off-label use in the US (already compendia listed) begins in 2013."

Celgene closed at $71.50 on Friday.

Latest Ratings for CELG

DateFirmActionFromTo
Oct 2017BarclaysMaintainsEqual-Weight
Oct 2017UBSMaintainsBuy
Oct 2017CitigroupDowngradesBuyNeutral

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (CELG)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...